EFFECTIVE PREEXCISION ALLOKINE-ALPHA THERAPY-INDUCED REDUCTION IN THE VIRAL LOAD DETERMINED BY THE HYBRID CAPTURE ASSAY IN PATIENTS WITH SEVERE CERVICAL INTRAEPITHELIAL NEOPLASIAS

Objective. To evaluate the efficiency of pre-excision antiviral and immunomodulatory therapy with allokine-alpha in the combination treatment of patients with CIN2-3/CIS from the change in the viral load (VL) measured by hybrid capture 2 (HC2) assay. Subjects and methods. The study enrolled 60 patients with CIN2-3/CIS having a positive HC2 assay and a VL of more than 20 RLU. Of them 32 patients received immunomodulatory therapy with allokine-alfa before Large Loop Excision of the Transformation Zone (LLETZ) (conization) and 28 control patients did not been treated with immunomodulators before the excision. Following 40-60 days, VL was measured again in all the patients. Results. After allokine-alfa treatment, the viral load decreased in the majority of patients (71.9%) and the negative assay was noted in 9.4% of cases. The median HP2 values dropped significantly from 340 to 68 RL U (р = 0.035). There was a tendency for lower effect rates with high VL values (р = 0.058). In the control group, the viral load did not decrease; 26 of the 28 showed its increase (р < 0.0001). Conclusion. Allokine-alfa treatment may be efficient in the preoperative preparation of patients with CIN2—3/ CIS before LLETZ or conization and results in a VL reduction in the majority of patients. Allokine-alpha may be also used to treat patients with productive papillomavirus infection and mild CIN under guidance of VL measured by HC2 assay.

CIN, CIN, papillomavirus infection, viral load, hybrid capture 2 assay, immunomodulatory therapy, alloferon